$CLX

Clorox (CLX) Q1 2027 Earnings Call Transcript

Clorox (CLX) reported Q1 2027 earnings, updating its outlook to reflect $240M in input cost inflation, driven by commodities and transportation. The company expects organic sales growth of 3.5% to 4.5% for the year, with a flat to slightly positive performance in the back half. Clorox also announced Fabian Garcia as its next CEO, effective January. The company is implementing cost savings and targeted pricing to mitigate inflationary pressures.

Original reporting
Published Nov 3, 2026, 4:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clorox (CLX) Q1 2027 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CLXBearishMed
01

Why it matters

Guidance indicates higher input costs but outlines mitigation steps; investors must weigh margin risk versus pricing actions.

02

Market read

Clorox's guidance may influence consumer‑staples sentiment and set a benchmark for cost‑inflation handling.

03

What to watch

Potential upside from new product launches and international market share gains not detailed in the call.

Relevance 7/10Novelty 7/10Timing: today

Background

The transcript is from Clorox's Q1 2027 earnings call, providing forward guidance and cost outlook.

Company-level read

Ticker impact

$CLXBearishMedium confidence
Context

Clorox disclosed Q1 2027 earnings call guidance, noting $240 M input cost inflation and flat-to‑minus‑2% organic sales for Q2.

Expected impact

likely downside pressure as input cost inflation exceeds prior expectations

Evidence & confidence

The $240 M cost inflation (~2.5x historical rate) signals margin compression; mitigation actions are forward‑looking and not yet quantified.

Market effects

Consumer staples may see broader cost‑inflation concerns, prompting analysts to reassess margin outlooks.

U.S. consumer‑goods sector could face modest pressure in the near term.

Limited to companies with similar commodity exposure; not a macro‑wide driver.

Counterpoint

If pricing power materializes faster than expected, Clorox could outperform peers despite cost headwinds.

Key entities

  • Clorox

    U.S. consumer‑goods company (ticker CLX) reporting earnings guidance.

  • Fabian Garcia

    Appointed incoming CEO of Clorox.

Related articles

$CLXMed

Clorox Now Expects Earnings Near the Low End of Its Forecast as Costs Rise. Should Dividend Investors Be Worried?

Clorox (CLX) reported Q1 FY2027 results with net sales up 33% YoY to $1.91B, driven by Gojo acquisition and ERP transition. Adjusted EPS was $1.55, beating estimates. The company maintained annual guidance but expects earnings near the low end. Long-term debt rose 60% due to Gojo acquisition. Dividend yield is 5.6%, with 49 years of consecutive raises.

$CLXMedAI 8/10

Why is Clorox stock climbing today?

Clorox (CLX) stock rose 1.2% in pre-market trading after reporting fiscal Q1 earnings of $1.55 per share, beating estimates by 45%, with revenue of $1.91B. Sales increased 33% YoY, driven by the GOJO acquisition and organic growth. Analysts upgraded price targets (Evercore ISI to $99, Wells Fargo to $90, JPMorgan to $86), but Goldman Sachs maintained a Sell rating with a $74 target. Management warned of higher input costs and adjusted EPS guidance downward.

$CLXHighAI 8/10

Clorox Co (CLX) (Q1 2027) Earnings Call Highlights: Record Cost Savings and GoJo

Clorox (CLX) reported Q1 2027 earnings, with CEO Linda Rendell and CFO Kevin Bellet discussing organic sales growth of 3.5% to 4.5%, including ERP benefits. They highlighted record cost savings, targeted pricing, and market share improvements in home care and Brita. GoJo synergies are progressing faster than expected, with revised EPS estimates. The company aims for long-term gross margin of 43% to 44% and operating margin of 18%.

$CLXMed

Clorox Q1 Earnings Call Highlights

Clorox (CLX) maintained its fiscal-year organic-sales-growth outlook of 3.5% to 4.5%, with Q2 expected to range from flat to down 2%. The company reported share gains in home care, Brita, and Hidden Valley Ranch, while Kingsford and cat litter faced challenges. Clorox is prioritizing pricing, innovation, and GOJO integration, with Fabian Garcia appointed as the next CEO. The company expects positive adjusted EPS impact from synergies in fiscal 2027.